Name: Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells (Video) | JoVE Journal
Uploaded: 2014-01-29T14:00:00.000+00:00
Duration: 6 min 29 s
Description: Learn quantitative methods for detecting antibody-induced complement activation on red blood cells using flow cytometry and spectrometry. These assays improve diagnostic precision for immunology and hematology research.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

SZ and DW receive an unrestricted grant of Viropharma.

1. Preparation of Bromelain-treated Red Blood Cells
<ol>
	<li>Wash 0-typed red blood cells 3x with 1x PBS (centrifugation at 664 x g for 2-5 min).</li>
	<li>Incubate 1 volume of packed RBCs with two volumes of a 0.5% bromelain solution for 10 min at 37 &#176;C.</li>
	<li>Wash the cells 3x with 1x PBS.</li>
	<li>The cells can be stored as a 3% solution at 4 &#176;C in 1x PBS for at least one week.</li>
</ol>
2. C3 and C4 Deposition Analysis on RBCs by FACS
<ol>
	<li>Heat-inactivate the required amount of patient serum (or other anti-RBC antibody source) by heating the sample for 30 min at 56 &#176;C.</li>
	<li>Wash bromelain-treated RBCs three times in VBG- (5 mM Veronal, 150 mM NaCl, 0.05% gelatin pH 7.4) and resuspend them in VBG++ (VBG-- + 2 mM MgCl2 + 10 mM CaCl2) to give a 0.5% solution.</li>
	<li>Pipette the following components into a round-bottom plate with a glass pearl (for proper mixing): 25 &#181;l 0.5% RBCs, 37.5 &#181;l fresh AB serum (complement source) and 37.5 &#181;l 200 &#181;g/ml anti-C5. Anti-C5 is expensive and might be difficult to obtain. One could consider using C5-/C6-/C7- or C8-deficient serum instead of AB serum and anti-C5.</li>
	<li>Add patient serum per well to a final concentration of 0.1-33%. Correct for differences in serum concentration per well due using heat-inactivated AB serum. Add VBG++ to get a final volume of 150 &#181;l/well. Close plate with ELISA foil.</li>
	<li>Incubate 1.5-2 hr at 37 &#176;C while shaking.</li>
	<li>Wash the RBCs three times with PBS + 0.5% BSA (centrifugation at 664 x g for 2 min).</li>
	<li>Add fluorescently labeled anti-C3 and anti-C4 monoclonal antibodies or their Fab fragments (to reduce agglutination) in PBS + 0.5% BSA to a final concentration of 1 &#181;g/ml. Here custom developed anti-C3-Alexa Fluor 488 and anti-C4-Alexa Fluor 647 monoclonal antibodies are used; the choice of these fluorescent labels allows simultaneous detection of C3 and C4 by FACS.</li>
	<li>Incubate 30-45 min at room temperature with gentle shaking.</li>
	<li>Wash RBCs 3x with PBS + 0.5% BSA.</li>
	<li>Resuspend RBCs 150 &#181;l in PBS +0.5% BSA and pipette them into a new plate (to get rid of the glass pearls before FACS analysis).</li>
	<li>Perform FACS analysis. Separate single cells from doublets in a scatter plotting FSC-A; set the gate on the single RBCs; select the appropriate detection channel for the fluorescence signals (e.g. FITC and APC).</li>
	<li>Quantify results using the median fluorescence intensity.</li>
</ol>
Note: It is possible to use an isotype control (e.g. fluorescently labeled anti-IL6 mouse IgG1). However, it is recommended to include a true negative control e.g. by incubating RBCs without patient serum (only AB serum) or without a complement source (heat-inactivated AB serum and heat-inactivated patient serum), and then stain these with the same anti-C3-Alexa Fluor 488 and anti-C4-Alexa Fluor 647 antibodies. This gives a more valid control than an isotype control in the case of red blood cells12, although these different controls typically give the same, negative outcome.
3. Quantitative Hemolytic Assay
<ol>
	<li>Heat-inactivate the required amount of patient sera (or other anti-RBC antibody source) by heating the sample 30 min at 56 &#176;C.</li>
	<li>Wash RBCs 3x with VBG-- and once with VBG++.</li>
	<li>Pipette the following components into a round-bottom plate with a glass pearl (for proper mixing): 35 &#181;l 3% RBCs, 25 &#181;l fresh AB serum (complement source) and 1-50% patient serum. Correct for differences in serum concentration using heat-inactivated AB serum. Add VBG++ to get a final volume of 150 &#181;l/well. Close plate with ELISA foil.</li>
	<li>Incubate at 37 &#176;C for 1.5-2 hr with shaking.</li>
	<li>Centrifuge plate at 664 x g for 5 min with reduced deceleration (e.g. deceleration to full stop in 2-3 min).</li>
	<li>Carefully pipette 90 &#181;l supernatant in a new microtiter plate. It is important at this step to prevent air bubbles and to prevent to take along intact cells.</li>
	<li>Measure A414/690 in a suitable spectrophotometer.</li>
	<li>Express the lysis as a percentage of the lysis of a sample RBCs with pure water.</li>
</ol>

<ol><li>Zeerleder, S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Autoimmune+haemolytic+anaemia+-+a+practical+guide+to+cope+with+a+diagnostic+and+therapeutic+challenge%5BTitle%5D)+AND+%22Neth.+J.+Med%22%5BJournal%5D)">Autoimmune haemolytic anaemia - a practical guide to cope with a diagnostic and therapeutic challenge.</a> Neth. J. Med. 69 (4), 177-184 (2011).</li>
<li>Reardon, J. E., Marques, M. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Laboratory+evaluation+and+transfusion+support+of+patients+with+autoimmune+hemolytic+anemia%5BTitle%5D)+AND+%22Am.+J.+Clin.+Pathol%22%5BJournal%5D)">Laboratory evaluation and transfusion support of patients with autoimmune hemolytic anemia.</a> Am. J. Clin. Pathol. 125, 71-77 (2006).</li>
<li>Lai, M., Leone, G., Landolfi, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Autoimmune+hemolytic+anemia+with+gel-based+immunohematology+tests%5BTitle%5D)+AND+%22Am.+J.+Clin.+Pathol%22%5BJournal%5D)">Autoimmune hemolytic anemia with gel-based immunohematology tests.</a> Am. J. Clin. Pathol. 139 (4), 457-463 (2013).</li>
<li>Zantek, N. D., Koepsell, S. A., Tharp Jr,, R, D., Cohn, C. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+direct+antiglobulin+test%3A+A+critical+step+in+the+evaluation+of+hemolysis%5BTitle%5D)+AND+%22Am.+J.+Hematol%22%5BJournal%5D)">The direct antiglobulin test: A critical step in the evaluation of hemolysis.</a> Am. J. Hematol. 87 (7), 707-709 (2012).</li>
<li>Natukunda, B., Brand, A., Schonewille, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Red+blood+cell+alloimmunization+from+an+African+perspective%5BTitle%5D)+AND+%22Curr.+Opin.+Hematol%22%5BJournal%5D)">Red blood cell alloimmunization from an African perspective.</a> Curr. Opin. Hematol. 17 (6), 565-570 (2010).</li>
<li>Packman, C. H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Hemolytic+anemia+due+to+warm+autoantibodies%5BTitle%5D)+AND+%22Blood+Rev%22%5BJournal%5D)">Hemolytic anemia due to warm autoantibodies.</a> Blood Rev. 22 (1), 17-31 (2008).</li>
<li>Berentsen, S., Tjønnfjord, G. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Diagnosis+and+treatment+of+cold+agglutinin+mediated+autoimmune+hemolytic+anemia%5BTitle%5D)+AND+%22Blood+Rev%22%5BJournal%5D)">Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia.</a> Blood Rev. 26 (3), 107-115 (2012).</li>
<li>Petz, L. D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cold+antibody+autoimmune+hemolytic+anemia%5BTitle%5D)+AND+%22Blood+Rev%22%5BJournal%5D)">Cold antibody autoimmune hemolytic anemia.</a> Blood Rev. 22 (1), 1-15 (2008).</li>
<li>Barros, M. M. O., Blajchman, M. A., Bordin, J. O. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Warm+autoimmune+hemolytic+anemia%3A+recent+progress+in+understanding+the+immunobiology+and+the+treatment%5BTitle%5D)+AND+%22Transfus.+Med.+Rev%22%5BJournal%5D)">Warm autoimmune hemolytic anemia: recent progress in understanding the immunobiology and the treatment.</a> Transfus. Med. Rev. 24 (3), 195-210 (2010).</li>
<li>Endoh, T., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Optimal+prewarming+conditions+for+Rh+antibody+testing%5BTitle%5D)+AND+%22Transfusion%22%5BJournal%5D)">Optimal prewarming conditions for Rh antibody testing.</a> Transfusion. 46 (9), 1521-1525 (2006).</li>
<li>Wouters, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((C1-esterase+inhibitor+concentrate+rescues+erythrocytes+from+complement-mediated+destruction+in+autoimmune+hemolytic+anemia%5BTitle%5D)+AND+%22Blood%22%5BJournal%5D)">C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia.</a> Blood. 121 (7), 1242-1244 (2013).</li>
<li>Arndt, P. A., Garratty, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+Critical+Review+of+Published+Methods+for+Analysis+of+Red+Cell+Antigen-Antibody+Reactions+by+Flow+Cytometry%2C+and+Approaches+for+Resolving+Problems+with+Red+Cell+Agglutination%5BTitle%5D)+AND+%22Transfus.+Med.+Rev%22%5BJournal%5D)">A Critical Review of Published Methods for Analysis of Red Cell Antigen-Antibody Reactions by Flow Cytometry, and Approaches for Resolving Problems with Red Cell Agglutination.</a> Transfus. Med. Rev. 24 (3), 172-194 (2010).</li>
</ol>

The authors have nothing to disclose.

The above assays are reproducible and robust. They are easy to perform and it is possible to perform them with many samples at the same time (in a 96-well plate). Hence, this approach would also be suitable for a fully automated system, e.g. an ELISA robot system. In contrast to the currently used techniques, these assays are quantitative and this will help e.g. in the study of the effect of complement inhibitors. Moreover, the interpretation is objective, which is an improvement over the currently used...

Antibodies against red blood cells (RBCs) can be induced by transfusion of RBCs expressing an antigen which is not present on recipient RBCs. These allo-antibodies can cause severe acute hemolytic transfusion reactions due to complement activation upon the following transfusion5. In auto-immune hemolytic anemia (AIHA), patients have auto-antibodies against their own RBCs. This leads to accelerated clearance of the cells via the interaction of IgG bound to RBCs with Fc&#947;-receptors on phagocytes in the spleen and/or in case of auto-antibodies able to activate complement via complement receptors in the liver6,7. Fulminant complement activation resulting in intravascular hemolysis is rare but often fatal. Accelerated, complement mediated RBC destruction induced by either allo- or autoantibodies results in acute anemia and hence potentially fatal tissue hypoxia. The auto-antibodies in AIHA are classified in warm and cold antibodies, depending on the optimal temperature they bind to RBCs (37 &#176;C or lower, respectively). The warm antibodies are usually of IgG isotype and the cold antibodies of the IgM isotype8,9. AIHA can be secondary to e.g. lymphoprolyferative disorders, connective tissue diseases, solid tumors, infections or drugs, but in 50% of the cases AIHA is idiopathic9.
Detection of gammaglobulins (e.g. IgG or IgM) and complement bound to patient&#39;s RBCs is performed by means of a semiquantitative direct antiglobulin (Coombs) test (DAT). In the DAT patient RBCs are incubated with anti-IgG or anti-C3d. Occurrence of RBC agglutination demonstrates the presence of attached complement components or IgG binding. Detection of allo- or autoantibodies in the patient&#39;s serum is performed by means of the indirect antiglobulin test (IAT). In the IAT, bromelain-treated test RBCs are incubated with patient serum, washed and then incubated with anti-human IgG. In case RBCs have been sensitized with anti-RBC IgG present in the patient serum agglutination will occur. IgM antibodies to RBCs will directly lead to agglutination upon incubation of bromelain-treated test RBCs with patient serum. RBC agglutination in the direct Coombs test or in the IAT is visually assessed either by eye in a test tube or by loading the sample on a small Sephadex column separating agglutinated and single RBCs by size1.
Another frequently used technique to measure complement activation on RBCs is the hemolytic assay1, in which the capacity of patient serum to induce (complement-mediated) hemolysis of bromelain-treated RBCs10 is assessed. The test is noted as positive when the supernatant after centrifugation is stained red due to released hemoglobin and considered to be negative if it remains colorless. Both the antiglobulin test and the hemolytic assay are semiquantitative, since the highest serum dilution is denoted in which the test is still positive.
The antiglobulin test and the hemolytic assay are robust assays that are routinely used in diagnostics. Since these assays are semiquantitative and dependent on the experience of the technician performing the assay they are not suitable to study subtle differences of complement activation on RBCs, as needed when evaluating the efficacy of complement inhibitors. Therefore, we developed two quantitative assays to determine the complement activation by (auto-)antibodies to RBCs, which we will describe in this paper.
First, we developed an assay to measure the deposition of activation fragments of complement C3 and C4 on RBCs (Figure 1A). In this assay, human bromelain-treated type-0 RBCs are incubated with heat-inactivated patient serum (anti-RBC antibody source), fresh AB serum (complement source) and anti-C5 monoclonal antibody (Eculizumab). During this incubation, C3 and C4 deposition will occur if the patient serum contains complement activating anti-RBC antibodies. In order to prevent RBC lysis by downstream complement activation a blocking anti-C5 monoclonal antibody is added. Next, C3 and C4 deposition on the RBCs is detected by FACS using fluorescently labeled monoclonal antibodies or Fab-fragments reacting with C3 and C4, respectively. Gating on single RBCs is important to ensure the reliability of the results. Advantages of this technique include that a small volume of patient material is required, complement activation at an early stage of the cascade is assessed and the method is reproducible and quantitative. An additional advantage of looking at both C3 and C4 is that a distinction can be made between the classical and lectin pathway activation (both C3 and C4 deposition) and the alternative pathway activation (only C3 deposition). The use of bromelain-treated RBCs instead of untreated RBCs increases the sensitivity of the assay.
The second assay is based on the currently used hemolytic assay (Figure 1B). Human bromelain-treated type-0 RBCs are incubated with heat-inactivated patient serum (anti-RBC antibody source) and fresh AB serum (complement source). If complement is activated by patient anti-RBC antibodies, dose dependent RBC lysis will occur, leading to release of hemoglobin. The amount of released hemoglobin is quantified by measuring its absorbance at 414 nm in the supernatant after spinning down the intact and fragmented RBCs. The absorbance correlates with the amount of occurred hemolysis. In contrast to the currently used assay, this protocol allows for an objective, quantitative value of hemolysis that is very reproducible and not dependent on the person interpreting the assay.
An application of these methods has been described in 11, where the potential use of C1-inhibitor as complement inhibitor in AIHA was studied.

<table><tbody><tr><td>PBS</td><td>Fresenius Kabi</td><td></td><td>&amp;nbsp;</td></tr><tr><td>BSA</td><td>Sigma</td><td>B-4287</td><td>&amp;nbsp;</td></tr><tr><td>Barbital</td><td>Fagron</td><td>0261</td><td>This chemical is subject to drug regulation.</td></tr><tr><td>Sodium Barbital</td><td>Fagron</td><td>0263</td><td>This chemical is subject to drug regulation.</td></tr><tr><td>Gelatin</td><td>Merck</td><td>1.0470.0500</td><td>&amp;nbsp;</td></tr><tr><td>Sodium chloride</td><td>Merck</td><td>1.06404.1000</td><td>&amp;nbsp;</td></tr><tr><td>Magnesium Chloride</td><td>Merck</td><td>1.05833.0250</td><td>&amp;nbsp;</td></tr><tr><td>Calcium chloride</td><td>Merck</td><td>1.0238.0500</td><td>&amp;nbsp;</td></tr><tr><td>Dylight 488 amine reactive dye</td><td>Pierce</td><td>46402</td><td>&amp;nbsp;</td></tr><tr><td>Dylight 650 amine reactive dye</td><td>Pierce</td><td>62265</td><td>&amp;nbsp;</td></tr><tr><td>&amp;alpha;C5 (Eculizumab)</td><td>Alexion Pharmaceuticals</td><td></td><td>&amp;nbsp;</td></tr><tr><td>FACS (Canto)</td><td>BD</td><td></td><td>Any FACS can be used that has the appropiate lasers.</td></tr><tr><td>Spectrophotometer (e.g. Multiskan spectrum)&amp;nbsp;</td><td>Thermo Labsystems</td><td>1500-193</td><td>Any spectrophotometer with the right wavelength range can be used</td></tr><tr><td>BD FACSDiva software v 6.1.2</td><td>BD</td><td>643629</td><td>Any compatible FACS analysis software can be used</td></tr><tr><td>Bromelain&amp;nbsp;</td><td>Sanquin</td><td>K1121</td><td>&amp;nbsp;</td></tr></tbody></table>

methods for quantitative detection of antibody-induced complement activation on red blood cells

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Antibodies against red blood cells (RBCs) can lead to complement activation resulting in an accelerated clearance via complement receptors in the liver (extravascular hemolysis) or leading to intravascular lysis of RBCs. Alloantibodies (e.g. ABO) or autoantibodies to RBC antigens (as seen in autoimmune hemolytic anemia, AIHA) leading to complement activation are potentially harmful and can be - especially when leading to intravascular lysis - fatal1. Currently, complement activation due to (auto)-antibodies on RBCs is assessed in vitro by using the Coombs test reflecting complement deposition on RBC or by a nonquantitative hemolytic assay reflecting RBC lysis1-4. However, to assess the efficacy of complement inhibitors, it is mandatory to have quantitative techniques. Here we describe two such techniques. First, an assay to detect C3 and C4 deposition on red blood cells that is induced by antibodies in patient serum is presented. For this, FACS analysis is used with fluorescently labeled anti-C3 or anti-C4 antibodies. Next, a quantitative hemolytic assay is described. In this assay, complement-mediated hemolysis induced by patient serum is measured making use of spectrophotometric&#160;detection of the released hemoglobin. Both of these assays are very reproducible and quantitative, facilitating studies of antibody-induced complement activation.

Figure 2A shows a representative scatter plot for RBCs. Suitable gating for single RBCs can be seen in de FSC-W - FSC-A plot (P1). Usually around 95% of the RBCs fall within this P1 gate (single cells), but when a high percentage of patient serum is used, this can drop to 70-80%, especially when anti-RBC IgM is present in the patient serum.
Representative results for the effect of AIHA patient serum on C4 deposition are shown in Figure 2B and on C3 deposition ...

Here we describe two assays for measuring complement activation induced by antibodies against red blood cells. The major advantage over the current assays is their quantitative and easy-to-interpret nature.

Antibodies against red blood cells (RBCs) can lead to complement activation resulting in an accelerated clearance via complement receptors in the liver ...

The overall goal of the following experiment is to assess complement activation by antibodies against red blood cells or RBCs in patient serum. This is achieved by incubating red blood cells with patient serum in the presence of blocking anti C five antibody to induce C four and C3 deposition on the RBC surface. Next, the RBCs are stained with fluorescently labeled anti C four and anti C3 antibodies, and the amount of complement deposition on the RBCs can then be analyzed by flow cytometry in an alternative method.The RBCs are incubated with patient serum in the absence of anti C five to induce complement mediated lysis. The percentage of lysed RBCs can then be determined by measuring the amount of hemoglobin released by the cells by spectrometry. The main advantage of this new technique over existing methods such as the hemolysis or the antiglobulin test used in routine diagnostics is that it is quantitative in nature and we can detect suboptimal differences in complement activation.Elizabeth Brook postdoc in our lab will demonstrate procedures Begin by washing zero typed red blood cells three times with PBS, then incubate the pellet in 0.5%Roma lane solution at a one to two ratio for 10 minutes at 37 degrees Celsius after washing the cells three more times, store them as a 3%solution in fresh PBS at four degrees Celsius to analyze complement deposition on the RBCs by flow cytometry. First heat inactivate the desired amount of patient serum for 30 minutes at 56 degrees Celsius while the serum is being heat treated. Wash the brola treated red blood cells three times in Roal buffer after the final wash.Resus suspend the pellet in vbg plus plus at a 0.5%dilution. Next at a glass pearl 25 microliters of 0.5%RBCs 37.5 microliters of fresh AB serum and 37.5 microliters of 200 micrograms per milliliter, anti C five to each well of a 96 well round bottom plate. Then add the heat inactivated patient serum to each well at the appropriate concentration supplementing with heat inactivated AB serum as necessary and including a negative control as well.Use VBG plus plus to bring each well to a final volume of 150 microliters and then incubate the plate covered with E IA foil for one and a half to two hours at 37 degrees Celsius with shaking after the incubation. Wash the cells three times with PBS supplemented with 0.5%BSA, and then tag the cells with one microgram per milliliter. A fluorescently labeled anti C3 and anti C four monoclonal antibodies incubate the cells for 30 to 45 minutes at room temperature with gentle shaking, and then after washing the plate three times, resuspend the RBCs in 150 microliters of PBS plus 0.5%BSA per.Well transfer the cell suspensions to a new 96 well round bottom plate, and then load the plate onto the flow cytometer, separate the single cells from the doublets using a forward scatter plot. Set the gate on the single RBCs and then select the appropriate detection channel for the fluorescent signals. Quantify the results using the median fluorescence intensity for quantitative hemolytic analysis, heat and activate the patient serum and wash the romaine treated RBCs as just demonstrated.Then after incubating the RBCs with complement and patient serum as just demonstrated, but without the anti C five, spin down the cells for five minutes at 664 GS with reduced deceleration. Next, carefully transfer 90 microliters of supernatant to a new microtiter plate, taking care not to transfer the intact cells and to avoid creating air bubbles, and then measure the absorption at a four 14 to six 90 in a spectrophotometer express. The hemolysis as a percentage of the lysis of a sample of RBCs incubated in pure water.In this first figure, representative scatter plots for brola treated RBCs are shown suitable gating for single RBCs can be seen here. Typically, around 95%of the RBCs fall within this single cell gate. In these histograms representative results for the effect of autoimmune hemolytic anemia or aha.Patient serum on C four and C3 deposition are shown as expected, more patient serum leads to more complement deposition. Curiously, the complement deposition occurs in two distinct positive peaks. This is probably not caused by heterogeneity in the RBC population since the RBCs are drawn from a single donor, although the cause of this phenomenon is still being investigated, the median fluorescence intensities of the samples are plotted in these line graphs to show the reproducibility of the C four and C3 deposition assays.Note the wide variation in the deposition of the various AH H patient samples. Finally, data from a hemolytic assay of an ahha patient serum sample containing auto antibodies to RBCs can be observed in these graphs. Titration with the serum sample yields a clear reproducible curve with a suitable complement inhibitor such as anti C five.The hemolytic signal can be titrated away as demonstrated in this graph. After watching this video, you should have a good understanding of how to measure complement activation by red blood cell specific antibodies, either by flow cytometric analysis of C3 or C four deposition or by quantitative hemolytic assay.

methods-for-quantitative-detection-antibody-induced-complement

Research

JoVE Journal

Immunology and Infection

The classical pathway is activated by antibody and culminates in target cell lysis. The CH50 assay provides a measure of the complement activity of a serum sample. This video demonstrates the steps involved in determining the CH50 of a serum sample, the calculations and interpreting of results.

Measuring the 50% Haemolytic Complement (CH50) Activity of Serum

Source: Nagre, N., et al. Alveolar Macrophage Phagocytosis and Bacteria Clearance in Mice. J. Vis. Exp. (2019).This video demonstrates the assessment of complement receptor-mediated phagocytosis using sheep red blood cells opsonized with IgM and complement, followed by their uptake by mouse macrophages. The extent of phagocytosis is quantified by measuring a blue chromogenic product formed through hemoglobin-catalyzed oxidation of diaminofluorene.

Modeling Complement-Mediated Phagocytosis Using Opsonized Red Blood Cells In Vitro

This video demonstrates a technique to evaluate the complement-mediated bactericidal activity of antibodies present in serum. This approach combines isolated serum with pathogenic bacteria and exogenous complement proteins. Upon incubation, the bacteria are grown on an agar plate, and the produced colonies are quantified to measure the serum bactericidal titer.

A Serum Bactericidal Assay for the Complement-Mediated Bactericidal Activity of Antibodies

The video demonstrates a hemagglutination inhibition assay for detecting serum antibodies against specific antigens. Confirmation of hemagglutination inhibition in the test well and hemagglutination in the control well is achieved through distinct visual patterns. This assay plays a crucial role in assessing immune response, vaccine effectiveness, and studying viral infections in virology and immunology.

The Hemagglutination Inhibition Assay to Detect Serum Antibodies Against a Target Antigen

This video demonstrates an assay measuring the antibody-mediated activation of T cell effector functions. Adding an influenza virus hemagglutinin (HA)-specific monoclonal antibody to transfected mammalian cells expressing HA results in the formation of immune complexes with HA. Upon introducing engineered T cells expressing Fc receptors and a luciferase reporter, the T cells are activated by the antibody-HA complexes, and this activation is detected by adding a luciferase substrate and...

Measuring the Activation of Fc-Mediated Effector Functions by HA Antibodies

This video demonstrates an assay to measure the antibody-dependent cellular phagocytosis (ADCP) by breast milk phagocytes. Fluorescently labeled microspheres conjugated to an antigen-antibody complex, are combined with a cell suspension isolated from breast milk to induce antibody-dependent cellular phagocytosis by the phagocytic leukocytes. Upon labeling the cells with antibodies against common leukocyte antigen (CD45), flow cytometry is used to measure the fluorescence intensity of...

An In Vitro Assay to Measure Antibody-Dependent Cellular Phagocytosis by Phagocytes

The monocyte monolayer assay (MMA) is an in vitro assay that utilizes isolated primary monocytes obtained from mammalian peripheral whole blood to evaluate Fcγ receptor (FcγR)-mediated phagocytosis.

Use of a Monocyte Monolayer Assay to Evaluate Fc&#947; Receptor-mediated Phagocytosis

Here we describe methods using spinning disk confocal microscopy to image single phagocytic events by mouse resident peritoneal macrophages. The protocols can be extended to other phagocytic cells.

Time-lapse 3D Imaging of Phagocytosis by Mouse Macrophages

The aim of this method is to determine the CR1 density in the erythrocytes of any subject by comparing with three subjects whose erythrocyte CR1 density is known. The method uses flow cytometry after immunostaining of the subjects' erythrocytes by an anti-CR1 monoclonal antibody coupled to an amplified system using phycoerythrin (PE).

Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry

Capturing dynamic changes in the protein activation of enucleated red blood cells poses methodological challenges, like the preservation of dynamic changes to acute stimuli for later assessment. The presented protocol describes sample preparation and staining techniques that enable preservation and analysis of relevant protein changes and subsequent detection.

Immunostaining-Based Detection of Dynamic Alterations in Red Blood Cell Proteins

We have developed enhancements and updated methods for the existing monocyte-monolayer assay (MMA), in which macrophages are used to help better predict the clinical relevance of red cell alloantibodies in transfusion medicine and immunology. This assay is named the monocyte-macrophage assay (M-MA).

Prediction of Red Blood Cell Antibody Significance Using the Monocyte-Macrophage Assay

Learn quantitative methods for detecting antibody-induced complement activation on red blood cells using flow cytometry and spectrometry. These assays improve diagnostic precision for immunology and hematology research.

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Explore More Videos